Company / Operating Cash Flow
Amphstar Pharmaceuticals, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$156.1M
FY2025
5-year range
$89.2M / $213.4M
FY2021-FY2025
Trend
-26.8%
vs FY2024
Sector context
#44 of 216
Health Care
What the data says
Amphstar Pharmaceuticals, Inc.'s operating cash flow of $156M is higher than 80% of companies in the Health Care sector (FY2025). Operating Cash Flow has fluctuated over the past 10 years, ranging from $38M in FY2018 to $213M in FY2024.
Based on SEC 10-K filings.
$156M in FY2025 with a 5-year CAGR of +22.2%. Top quartile in the Health Care sector.
Declined from $184M to $156M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +20.5%
- 5-Year CAGR
- +22.2%
- 10-Year CAGR
- -
Sector benchmark
-76.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +22.2%, indicating consistent growth.
- In FY2025, operating cash flow decreased 26.8% year-over-year.
- Ranks #44 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2024.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $156.1M | -26.8% |
| FY2024 | $213.4M | +16.3% |
| FY2023 | $183.5M | +105.8% |
| FY2022 | $89.2M | -9.0% |
| FY2021 | $98.0M | +71.1% |
| FY2020 | $57.3M | +37.1% |
| FY2019 | $41.8M | +9.4% |
| FY2018 | $38.2M | -2.6% |
| FY2017 | $39.2M | +1.7% |
| FY2016 | $38.6M | +261.0% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026